Effects of 12 weeks' treatment with a proton pump inhibitor on insulin secretion, glucose metabolism and markers of cardiovascular risk in patients with type 2 diabetes: a randomised double-blind prospective placebo-controlled study

K D Hove; Charlotte Brøns; Kai Erik Vinther Færch; S S Lund; J S Petersen; A E Karlsen; Pia Rossing; J F Rehfeld; A Vaag

doi:10.1007/s00125-012-2714-y

Effects of 12 weeks' treatment with a proton pump inhibitor on insulin secretion, glucose metabolism and markers of cardiovascular risk in patients with type 2 diabetes: a randomised double-blind prospective placebo-controlled study

K D Hove, Charlotte Brøns, Kai Erik Vinther Færch, S S Lund, J S Petersen, A E Karlsen, Pia Rossing, J F Rehfeld, A Vaag

35 Citationer (Scopus)

Abstract

Recent studies suggest that proton pump inhibitor treatment may increase insulin secretion and improve glucose metabolism in type 2 diabetes. In a randomised double-blind prospective placebo-controlled 2 × 2 factorial study, we examined the effect of esomeprazole on insulin secretion, HbA(1c) and cardiovascular risk factors in type 2 diabetes.

Originalsprog	Engelsk
Tidsskrift	Diabetologia
Vol/bind	56
Udgave nummer	1
Sider (fra-til)	22-30
Antal sider	9
ISSN	0012-186X
DOI	https://doi.org/10.1007/s00125-012-2714-y
Status	Udgivet - 2013

Adgang til dokumentet

10.1007/s00125-012-2714-y

Fingeraftryk

Dyk ned i forskningsemnerne om 'Effects of 12 weeks' treatment with a proton pump inhibitor on insulin secretion, glucose metabolism and markers of cardiovascular risk in patients with type 2 diabetes: a randomised double-blind prospective placebo-controlled study'. Sammen danner de et unikt fingeraftryk.

Citationsformater

Hove, K. D., Brøns, C., Færch, K. E. V., Lund, S. S., Petersen, J. S., Karlsen, A. E., Rossing, P., Rehfeld, J. F., & Vaag, A. (2013). Effects of 12 weeks' treatment with a proton pump inhibitor on insulin secretion, glucose metabolism and markers of cardiovascular risk in patients with type 2 diabetes: a randomised double-blind prospective placebo-controlled study. Diabetologia, 56(1), 22-30. https://doi.org/10.1007/s00125-012-2714-y

Effects of 12 weeks' treatment with a proton pump inhibitor on insulin secretion, glucose metabolism and markers of cardiovascular risk in patients with type 2 diabetes: a randomised double-blind prospective placebo-controlled study. / Hove, K D; Brøns, Charlotte; Færch, Kai Erik Vinther et al.
I: Diabetologia, Bind 56, Nr. 1, 2013, s. 22-30.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Hove, KD, Brøns, C, Færch, KEV, Lund, SS, Petersen, JS, Karlsen, AE, Rossing, P, Rehfeld, JF & Vaag, A 2013, 'Effects of 12 weeks' treatment with a proton pump inhibitor on insulin secretion, glucose metabolism and markers of cardiovascular risk in patients with type 2 diabetes: a randomised double-blind prospective placebo-controlled study', Diabetologia, bind 56, nr. 1, s. 22-30. https://doi.org/10.1007/s00125-012-2714-y

@article{8e6b04a83f18456c93fefb822145e142,

title = "Effects of 12 weeks' treatment with a proton pump inhibitor on insulin secretion, glucose metabolism and markers of cardiovascular risk in patients with type 2 diabetes: a randomised double-blind prospective placebo-controlled study",

abstract = "Recent studies suggest that proton pump inhibitor treatment may increase insulin secretion and improve glucose metabolism in type 2 diabetes. In a randomised double-blind prospective placebo-controlled 2 × 2 factorial study, we examined the effect of esomeprazole on insulin secretion, HbA(1c) and cardiovascular risk factors in type 2 diabetes.",

author = "Hove, {K D} and Charlotte Br{\o}ns and F{\ae}rch, {Kai Erik Vinther} and Lund, {S S} and Petersen, {J S} and Karlsen, {A E} and Pia Rossing and Rehfeld, {J F} and A Vaag",

year = "2013",

doi = "10.1007/s00125-012-2714-y",

language = "English",

volume = "56",

pages = "22--30",

journal = "Diabetologia",

issn = "0012-186X",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "1",

}

TY - JOUR

T1 - Effects of 12 weeks' treatment with a proton pump inhibitor on insulin secretion, glucose metabolism and markers of cardiovascular risk in patients with type 2 diabetes

T2 - a randomised double-blind prospective placebo-controlled study

AU - Hove, K D

AU - Brøns, Charlotte

AU - Færch, Kai Erik Vinther

AU - Lund, S S

AU - Petersen, J S

AU - Karlsen, A E

AU - Rossing, Pia

AU - Rehfeld, J F

AU - Vaag, A

PY - 2013

Y1 - 2013

N2 - Recent studies suggest that proton pump inhibitor treatment may increase insulin secretion and improve glucose metabolism in type 2 diabetes. In a randomised double-blind prospective placebo-controlled 2 × 2 factorial study, we examined the effect of esomeprazole on insulin secretion, HbA(1c) and cardiovascular risk factors in type 2 diabetes.

AB - Recent studies suggest that proton pump inhibitor treatment may increase insulin secretion and improve glucose metabolism in type 2 diabetes. In a randomised double-blind prospective placebo-controlled 2 × 2 factorial study, we examined the effect of esomeprazole on insulin secretion, HbA(1c) and cardiovascular risk factors in type 2 diabetes.

U2 - 10.1007/s00125-012-2714-y

DO - 10.1007/s00125-012-2714-y

M3 - Journal article

C2 - 23011351

SN - 0012-186X

VL - 56

SP - 22

EP - 30

JO - Diabetologia

JF - Diabetologia

IS - 1

ER -